MetaCap

Corcept Therapeutics (CORT) vs Mirum Pharmaceuticals (MIRM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 35.5% versus a loss of 17.7%. Over five years, MIRM leads with a +616.9% price change compared with +196.0% for CORT. Corcept Therapeutics is the larger company by market cap ($6.96 billion vs $6.28 billion), about 1.1 times the size, while Mirum Pharmaceuticals is growing revenue faster (+54.7% vs +12.8%).

On valuation, Corcept Therapeutics trades at a lower forward P/E (12.8x vs 300.4x for Mirum Pharmaceuticals). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -4.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CORT-17.69%MIRM+35.45%
+88%+11%-65%
Nov 21, 20251 yearNov 20, 2026
CORT+178.18%MIRM+512.68%
+737%+338%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CORT versus MIRM key metrics
MetricCORTMIRM
Share price$63.62$96.13
Market cap$6.96B$6.28B
1-day change-2.09%+0.65%
YTD return+82.82%+21.70%
1-year return-17.69%+35.45%
5-year return+196.04%+616.85%
P/E ratio (TTM)47.83—
Forward P/E12.77300.41
EPS (TTM)$1.33$-14.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$761.41M$521.31M
Revenue growth (YoY)+12.79%+54.74%
Net income (latest FY)$99.65M$-23.36M
Gross margin98.30%—
Operating margin5.88%-4.25%
Net margin13.09%-4.48%
52-week high$126.38$130.00
52-week low$28.66$63.23
Distance from 52-week high-49.66%-26.05%
Analyst consensusbuystrong_buy
Avg. price target upside+124.14%+64.06%
Average volume1.26M692.51K
Shares outstanding109.44M65.28M
Employees730470
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed CORT by 53.1 percentage points over the past year.
  • Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -4.5 cents for Mirum Pharmaceuticals.
  • Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs +12.79%).

About Corcept Therapeutics

CORT stock →

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

CORT vs MIRM FAQ

Which is bigger, Corcept Therapeutics or Mirum Pharmaceuticals?

Corcept Therapeutics (CORT) is larger, with a market capitalization of $6.96B compared with $6.28B for Mirum Pharmaceuticals (MIRM).

Which stock has performed better over the past year, CORT or MIRM?

MIRM returned +35.45% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.

Are Corcept Therapeutics and Mirum Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons